Compare Novo Nordisk A/S (NVO) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Uber Technologies Inc — how do they compare? Novo Nordisk A/S trades at $44.89 (market cap $200.69B), while Uber Technologies Inc trades at $71.3 (market cap $149.37B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays a 3.98% dividend while Uber Technologies Inc pays none. Which is the better fit depends on your goals.
| NVO | UBER | |
|---|---|---|
Market Cap | $200.69B | $149.37B |
Sector | Health | Industrials |
52-Week High | $63.98 | $100.10 |
52-Week Low | $35.29 | $65.94 |
Enterprise Value | $215.49B | $158.71B |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Uber's stock trades at $71.08, down 6.18% today, amid a bearish technical signal but strong fundamentals. Revenue grew to $52.02B in 2025 with a net income of $10.05B, though Q4 2025 earnings missed expectations. Recent news highlights strategic shifts toward autonomous vehicles, including robotaxi pilots in Spain and Germany, alongside cost-cutting measures like HR layoffs and AI spending caps.
The outlook is mixed: robust revenue growth and a dominant market position support upside, but competitive pressures, regulatory risks, and a projected negative cash flow in 2026 pose challenges. Analyst consensus is strongly bullish with a $102.56 price target, suggesting significant potential if execution aligns with autonomous vehicle initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
